Document:

exv10w16

 

Exhibit 10.16

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

LICENSE AGREEMENT

     THIS AGREEMENT is made and entered into effective March 7, 2003 (“Effective Date”) by
Mitsubishi Electric Research Laboratories, Inc. (“MERL”), a Delaware corporation, having its
principal place of business at 201 Broadway, Cambridge, MA 02139 and AutoCath, Inc. (“AutoCath”), a
Delaware corporation, having its principal place of business at 811 Hansen Way, Building 2, Palo
Alto, California 94304.

     1. Definitions.

          1.1 “Licensed Patents” means (i) [*], (ii) any and all domestic applications and foreign
counterparts related to either of the foregoing, including, without limitation, any continuations,
continuations-in-part and divisions, (iii) and any patents issuing from any of the foregoing
including, without limitation, reissues, registrations, reexamination certificates and extensions.

          1.2 “Product(s)” means any apparatus (or part thereof) that embodies and is covered by a claim
of an issued, unexpired Licensed Patent, excluding any claims that have been ruled invalid in a
final judicial determination.

          1.3 “Royalty-Bearing Product(s)” means any Product(s) other than [*], such as, for example,
[*] and [*].

          1.4 “Licensed Field of Use” means therapeutic or diagnostic vascular or endoluminal
intervention involving robotics, automation and/or telemanipulation.

          1.5 “Territory” means worldwide.

          1.6 “Net Revenues” means Royalty-Bearing Product revenues recognized by AutoCath and its
sublicenses during the relevant measurement period. Net Revenues shall be determined in accordance
with generally accepted accounting principles consistently applied and shall exclude only
sales, excise and use taxes and similar governmental assessments, transportation and insurance
charges and discounts, commissions, allowances, refunds and returns actually paid or allowed. Net
Revenue shall also include, for all Royalty-Bearing Products materially used by AutoCath and its
sublicenses (excluding Products used by AutoCath or its sublicensees for clinical trials or other
experimental, testing or developmental purposes), and not otherwise taken into account in
determining Net Revenue, an amount equivalent to that for which the Product would have been sold by
AutoCath or its applicable sublicensee if sold in the ordinary course of business. For avoidance of
doubt, normal distribution and end user agreements will not be deemed sublicenses hereunder. In any
case where the price of a Royalty-Bearing Product is not separately stated (e.g., if a
Royalty-Bearing Product is sold with or combined with other materials or technology for a single
price), Net

1.

 

Revenue shall mean AutoCath’s or its sublicensee’s average Net Revenue per Royalty-Bearing
Product when sold separately during the period covered by the applicable royalty report. However,
if AutoCath and its sublicensees have no separate sales of the Royalty-Bearing Product in any such
instances for the period, the Net Revenue for the Royalty-Bearing Product shall be determined by
reasonably allocating the amount received between the Royalty-Bearing Product and the other
material or technology based on the respective manufacturing costs thereof.

          1.7 “Confidential Information” means information disclosed by a party (“Discloser”) to
the other (collectively, “Recipient”) pursuant to this Agreement which information is marked with
“Confidential”, “Proprietary” or other similar legend. If Confidential Information is orally
disclosed, it shall be identified as such at the time of disclosure and a brief written description
and confirmation of the confidential nature of the information shall be sent to the Recipient
within 30 days after the disclosure. Confidential Information, however, shall not include any
information which: (1) is known to the Recipient at the time of its disclosure to the Recipient;
(2) is or becomes publicly known through no wrongful act of the Recipient; (3) is received from a
third party without a restriction on its disclosure; (4) is independently developed by the
Recipient or an affiliate of the Recipient; (5) is furnished to any third party by the Discloser
without a similar restriction on such third party’s rights; or (6) is approved for release by the
prior written consent of the Discloser.

     2. License; Commercialization.

          2.1 In consideration of AutoCath’s obligations under this Agreement, MERL hereby grants to
AutoCath an exclusive, nontransferable (subject to Section 17) license in the Licensed Field of Use
to exercise and exploit the Licensed Patents and related know-how, if any, in the Territory. Such
license includes the right to develop, use and make, have made, market, import and sell Products
and to allow OEMs, distributors and other resellers and end users who purchase Products from
AutoCath to use, market, import and resell Products and includes the right to grant sublicenses in
accordance with Section 4. AutoCath may, at its option, convert the foregoing license to a
non-exclusive license upon notice to MERL. To enable AutoCath to exercise the License, MERL shall
promptly disclose and provide to AutoCath all available information in its possession relating to
the Licensed Patents and the subject matter claimed therein.

          2.2 While the license granted herein remains exclusive and royalty-bearing, AutoCath will,
directly or through others, use reasonable commercial efforts to commercialize Royalty-Bearing
Product in the Territory. MERL’s sole remedy under any legal or equitable theory for AutoCath’s
failure to comply with the foregoing obligation shall be to terminate this Agreement as provided in
Section 6.2.

     3. Payment/Royalties.

          3.1 Milestone Payments.

               (a) AutoCath shall pay MERL a one-time payment of [*] within [*] days of the end of the first
calendar year in which Net Revenue in such calendar year exceeds [*].

2.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

               (b) AutoCath shall to pay MERL a one-time payment of [*] within [*] days of the end of the
first calendar year in which Net Revenue in such calendar year exceeds [*].

          3.2 Royalty. Subject to the terms and conditions of this Agreement, AutoCath shall pay
to MERL a running royalty at the rate of [*] of Net Revenue. Royalties shall be determined and paid
on a quarterly basis, commencing on the Effective Date. Each payment shall he made within [*] days
of the end of the applicable quarter and shall be accompanied by a royalty report, such a report to
be provided by AutoCath to MERL within such [*]-day period whether or not AutoCath enjoyed any Net
Revenues during the applicable period. Late payments under this or any other section of this
Agreement shall bear interest at the rate of [*] percent ([*]%) per month from the due dates until
paid.

          3.3 Minimum Royalty Payments. On the Effective Date, and on each anniversary
thereafter while the license hereunder remains exclusive, AutoCath shall pay MERL an up-front
minimum royalty payment of [*], which shall be fully creditable against royalties payable the
one-year period commencing on such date. The foregoing up-front minimum royalty payment shall be
reduced to [*] per year if the license becomes non-exclusive. All payments under this section shall
he made within [*] days of the applicable date.

          3.4 Equity. A further consideration for the license granted in this Agreement, subject
to execution of a customary letter by MERL confirming securities law-related investment
representations and a market standoff agreement, AutoCath shall issue to MERL [*] shares (as
currently constituted) of common stock in AutoCath promptly after the execution of this Agreement.

          3.5 Books and Records., Audit Rights. AutoCath shall maintain adequate records in
accordance with generally accepted accounting principles consistently applied with respect to its
obligation to make royalty payments under this Agreement. MERL shall have the right no more than
once per year to audit such records upon reasonable notice to AutoCath and at MERL’s expense using
a reputable independent auditing firm of its choice that is bound to a confidentiality agreement
reasonably acceptable to AutoCath. Such audit may he conducted for any royalty period up to two
years thereafter, and such audit may be conducted no more than once for any such period. In the
event any such audit discloses any underpayment by AutoCath of any royalty payment, AutoCath shall
immediately pay to MERL the underpaid amount with interest at the rate of [*] percent ([*]%) per
month from the original due date of such underpayment until paid. In the event the underpayment is
more than [*] percent ([*] %) of the amount due and payable, AutoCath shall also reimburse MERL for
the cost of such audit.

          3.6 Royalty Cap. AutoCath’s aggregate maximum obligation to MERL for royalties under
Section 3.2 (including minimum royalty payments) shall not exceed [*] in any given year (measured
from each anniversary of the Effective Date) (the “Royalty Cap”). After the Royalty Cap has been
accrued or paid in any year, no further royalties shall accrue or be payable in such year.

     4. Sublicensing. AutoCath may only sublicense the Licensed Patents only in conjunction
with a license of other AutoCath intellectual property. Sublicenses granted pursuant

3.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

to this article shall contain provisions consistent with this agreement with respect to field
of use, audit rights (running to AutoCath), termination and confidentiality, and such sublicenses
shall prohibit any sub-sublicensing. Within [*] days after granting any sublicense pursuant to this
provision, AutoCath shall provide a copy of the sublicense agreement to MERL, which shall be deemed
AutoCath Confidential Information.

     5. Patent Enforcement.

          5.1 MERL will use diligent efforts to prosecute and maintain the Licensed Patents and will
keep AutoCath informed of material developments.

          5.2 AutoCath shall have the right to prosecute and control (at its own expense) any action for
infringement of a Licensed Patent within the Licensed Field of Use while the license hereunder
remains exclusive. MERL and AutoCath, respectively, shall promptly give the other notice of each
infringement which it believes is being made of any Licensed Patent of which it is or becomes
aware. If AutoCath elects to commence such an action, MERL shall provide reasonable cooperation
with AutoCath in connection with any such action, including, without limitation, being joined as a
nominal party if necessary for AutoCath to maintain the action, at AutoCath’s expense and subject
to availability of its personnel, but AutoCath shall indemnify, defend and hold harmless MERL and
its affiliated companies from or against all defenses, claims and counterclaims resulting from its
action, provided that MERL gives AutoCath (or AutoCath otherwise has) prompt notice of any such
claim, reasonable cooperation at AutoCath’s expense, and sole control over defense and settlement
thereof. Should AutoCath at any time fail to defend any such claim or counterclaim using
reasonable diligence, and such failure is not cured within [*] days of notice, MERL shall have the
right to assume responsibility for the action, or such defense, at its option and at AutoCath’s
expense (provided such expenses are reasonably incurred). Recoveries as a result of such action
shall first be applied to reimburse AutoCath’s reasonable costs and expenses of the litigation,
with the remaining amount shared equally.

          5.3 In the event that AutoCath elects not to exercise its right to proceed against an
infringement of the Licensed Patents pursuant to Section 5.2, MERL may do so at its own expense
(and retain all recoveries) upon [*] days notice to AutoCath, provided that AutoCath does not
notify MERL of its intent to commence such an action within the notice period.

     6. Term and Termination.

          6.1 This Agreement shall continue in effect indefinitely unless and until terminated as
provided in this Section 6. This Agreement shall terminate (a) automatically upon the last to
expire of the Licensed Patents or at such time as every Licensed Patent has expired or been ruled
invalid in a final judicial determination or (b) upon ninety (90) notice by AutoCath to MERL if
AutoCath determines that it is economically or technically impractical or disadvantageous for it to
continue development or marketing regarding the Royalty-Bearing Products, or for any other reason;
provided that AutoCath shall be obligated to pay to MERL all amounts due under this Agreement to
the date of termination and shall not be entitled to any refund with respect amounts paid or
payable to that date. [*] represents and covenants that, under

4.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

no circumstances will it [*] or [*], directly or indirectly, any [*] to any of the [*].
Notwithstanding the foregoing, if [*] institutes litigation against [*] asserting that [*] any [*]
[*] shall not be precluded from defending such litigation by [*] the [*] of [*]. However, in no
event shall [*] seek to [*] of any [*] under the provisions of this Agreement by [*] the [*] of the
[*].

          6.2 If AutoCath materially breaches this Agreement and fails to cure such breach within sixty
(60) days after notice thereof from MERL to AutoCath, MERL may terminate this Agreement immediately
upon notice to AutoCath.

          6.3 Upon termination of this Agreement the license granted to AutoCath and all sublicense
granted by AutoCath pursuant to this Agreement shall terminate, and neither party shall have any
obligations to the other party, except for AutoCath’s payment obligations to the date of
termination, and other obligations of the parties that expressly by their terms survive termination
and claims and rights that exist by virtue of any breach of this Agreement. Notwithstanding any
termination hereof, in no event will AutoCath or any sublicensee or assignee be precluded from
disposing of its inventory or meeting its then existing supply obligations; provided that royalties
are paid to MERL as provided for in this Agreement with respect to each sale of a Royalty-Bearing
Product.

     7. Confidentiality; Ownership.

          7.1 Each party acknowledges that it may have access to the other party’s Confidential
Information in the course of performing its responsibilities under this Agreement. Recipient shall
not disclose to any other person, firm or corporation (other than to its employees and agents, with
a need to know and who receive such information subject to a suitable confidentiality agreement) or
use for its own benefit, any Confidential Information received from Discloser. Recipient shall only
use the Discloser’s Confidential Information in order to perform its obligations under this
Agreement. All Confidential Information is and shall remain the property of the Discloser. In the
event Recipient receives or is served with any request seeking production of the Discloser’s
Confidential Information, whether by subpoena, discovery request or other judicial, governmental or
administrative proceeding, before complying with such request, Recipient shall first notify
Discloser of any such request and shall cooperate fully with Discloser if Discloser elects to
contest such discovery request or seek entry of a protective order.

          7.2 Each party shall retain ownership of all of its technology and intellectually property,
and neither party shall have any right or license in the other’s technology or intellectual
property except as expressly provided in this Agreement.

     8. Representations. MERL represents and warrants to AutoCath that MERL (i) has an
assignment of the Licensed Patents and has not assigned, transferred, licensed, pledged or
otherwise encumbered the Licensed Patents in any way that would conflict with the license and other
rights granted in this Agreement, (ii) has full power and authority to enter into this Agreement
and to grant the rights and licenses granted herein and (iii) is not aware of infringement of any
of the Licensed Patents or any patents that dominate any of the Licensed Patents (excluding any
information conveyed by AutoCath to MERL in connection with the negotiation of this Agreement).

5.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

     9. Notices. Whenever under the terms of or in connection with this Agreement any
notice, consent, approval, authorization or other information is proper or required to be given by
either party, such notice, consent, approval, authorization or other information shall be in
writing and shall be given or made by facsimile, by reputable overnight courier with documentation
of receipt to the intended recipient thereof or by registered or certified mail, return receipt
requested, and with all postage prepaid, addressed as follows:

	 	 	 
	     If to MERL, to:

	 	Mitsubishi Electric Research Laboratories, Inc.
	 

	 	201 Broadway
	 

	 	Cambridge MA 02139
	 

	 	Attention: President
	 

	 	Facsimile: 617-621-7550
	 
	 	 
	     with copy to:

	 	Mitsubishi Electric & Electronics USA, Inc.
	 

	 	5665 Plaza Drive, P.O. Box 6007
	 

	 	Cypress CA 90630
	 

	 	Attention: General Counsel
	 

	 	Facsimile: 714-236-6169
	 
	 	 
	     If to AutoCath, to:

	 	AutoCath, Inc.
	 

	 	811 Hansen Way, Building 2
	 

	 	Palo Alto, California 94304
	 

	 	Attention: Fred Moll
	 

	 	Facsimile: (650) 565-7020

or to such other address for either party as may be supplied by notice given in accordance
herewith. Notice shall he deemed received on the date of receipt or the date on which receipt is
refused. In the event notice is given by facsimile, a copy of such facsimile shall be sent to the
recipient thereof in accordance with the provisions hereof (other than by facsimile) within two
days after such facsimile was transmitted.

     10. Survival. Notwithstanding the expiration or termination of this Agreement, those
rights and obligations which by their nature are intended to survive such expiration or termination
shall survive, including, but not limited to, the provisions of Articles 3, 5, 7, 9, 10, 12, 13,
15, 16, 18, 19 through 20 and Section 6.3.

     11. Export Controls. If AutoCath is required to engage in any export, in performing
work under this Agreement, AutoCath shall be responsible for complying with the United States
Export Administration Act, as amended, and with the Export Administration Regulations promulgated
thereunder, as amended, and with all other export laws and regulations of the United States and all
amendments, modifications or additions thereto, including, without limitation, all laws and
regulations relating to re-export. AutoCath shall indemnify and hold harmless MERL from all
liabilities, damages, costs and expenses reasonably incurred arising from or connected to any claim
against MERL resulting from any breach by AutoCath of its obligations under this section. MERL
shall keep AutoCath reasonably informed and, to the extent reasonably practicable, consult with
AutoCath regarding the defense and settlement of any such claim. AutoCath shall execute any
documents reasonably requested by the MERL

6.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

(including, without limitation, written assurances of non-reexportation except as permitted by
and in accordance with applicable law) for the purpose of complying with the United States laws and
regulations referred to herein.

     12. Disputes. Any litigation instituted to enforce or otherwise in connection with
this Agreement shall be filed in a state or federal court of general jurisdiction sitting in [*].
Both parties consent to the jurisdiction of such courts and to venue for such litigation in such
county and agree not to pursue litigation in any other forum.

     13. Governing Law and Attorneys’ Fees.

          13.1 This Agreement and the rights and obligations of the parties to and under this Agreement
shall be construed and interpreted in all respects in accordance with the laws of the State of
California and United States patent law, as applicable, without regard to the principles of
conflicts of law.

          13.2 In the event litigation should occur, the prevailing party in such litigation shall be
entitled to recovery from the other party all costs incurred by the prevailing party, including,
without limitation, all attorneys’ fees and costs.

     14. Relationship of the Parties. The relationship between MERL and AutoCath is that of
independent contractors. This Agreement does not establish a joint venture, agency or partnership
between the parties, nor does it create an employer-employee relationship. Unless specifically
provided in this Agreement or authorized in writing by an officer or other authorized employee of
MERL, AutoCath shall have no authority or power to bind MERL, to create a liability against MERL,
to incur any obligations on behalf of MERL or to represent that MERL is in any way responsible for
AutoCath and AutoCath shall not hold itself out as having any such authority.

     15. Severability. If any provision or part of any provision of this Agreement shall be
determined to be illegal, invalid or unenforceable in any respect, such determination of
illegality, invalidity or unenforceability shall not affect any other provision of this Agreement.
If part of a provision is deemed illegal, invalid or unenforceable, the balance of that provision
shall not be so affected. All surviving provisions shall remain in full force and effect as if this
Agreement had been executed without such illegal, invalid or unenforceable provision or part
thereof.

     16. No Waiver. No waiver of, or the failure of either party to require, strict
compliance with, any provision of this Agreement in any respect shall be deemed to be a waiver of
such party’s right to insist upon strict compliance with such provision or with all other
provisions of this Agreement. No waiver by either party of any breach or default of this Agreement
shall constitute a waiver of any other or subsequent breach or default. No waiver shall be binding
unless executed in writing by the party against whom the waiver is sought to be enforced.

     17. Assignment. Neither party shall assign, pledge or otherwise transfer any of its
rights, interests or obligations under this Agreement to any third party without the other

7.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

party’s prior written consent, except to a successor to all or substantially all of such
party’s assets or business.

     18. Entire Agreement. This Agreement contains all of the covenants, agreements and
understandings between the parties with respect to the subject matter of this Agreement and may not
be changed, modified, altered or terminated, except by a written agreement duly executed by the
parties. This Agreement supersedes any and all other agreements and understandings, whether written
or oral, between the parties with respect to the subject matter of this Agreement, including any
prior course of dealing or usage of trade, all prior or contemporaneous oral agreements between the
parties, and all prior written agreements between the parties with respect to the subject matter of
this Agreement.

     19. Headings. All headings are included for convenience only and shall not be
considered in any question of construction or interpretation of this Agreement.

     20. Construction. Each party acknowledges that it has had the opportunity to have
legal counsel review this Agreement and to negotiate its terms and conditions. Should any questions
of construction or interpretation of this Agreement arise, the parties agree that no presumption
shall be applied against the party drafting this Agreement or any portion thereof and that the
language of this Agreement shall, in all cases, be construed as a whole according to its fair
meaning and not strictly for or against either party.

     21. Authorization. Each party represents that the individual executing this Agreement
on its behalf is duly authorized to bind such party to this Agreement according to its terms.

8.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.

 

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the day and year
first above written.

	 	 	 	 	 	 	 
	MITSUBISHI ELECTRIC RESEARCH

LABORATORIES, INC.	 	AUTOCATH, INC.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Richard Waters
	 	By:
	 	/s/ Stephen Ghiglieri
	 

	 	 
	 	 	 	 
	Name:

	 	Richard Waters
	 	Name:
	 	Stephen Ghiglieri
	 

	 	 
	 	 	 	 
	Title:

	 	President/CEO
	 	Title:
	 	CFO
	 

	 	 
	 	 	 	 

9.

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended.exv10w17

 

Exhibit 10.17

LOAN AND SECURITY AGREEMENT

     THIS LOAN AND SECURITY AGREEMENT (the “Agreement”) dated as of the Effective Date, by and
among GOLD HILL VENTURE LENDING 03, LP (“Gold Hill”); SILICON VALLEY BANK, a California-chartered
bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054
(“SVB”) (SVB and the Gold Hill each individually a “Lender, ” and collectively the “Lenders”), SVB
in its capacity as agent (the “Agent”), and HANSEN MEDICAL, INC., a Delaware corporation, whose
address is 380 North Bernardo Avenue, Mountain View, CA 94043 (“Borrower”) provides the terms on
which Lenders shall lend to Borrower and Borrower shall repay Lenders. The parties agree as
follows:

1. ACCOUNTING AMD OTHER TERMS

     Accounting terms not defined in this Agreement shall be construed following GAAP. Calculations
and determinations must be made following GAAP. The term “financial statements” includes the notes
and schedules. The terms “including” and “includes” always mean “including (or includes) without
limitation, ” in this or any Loan Document. Capitalized terms in this Agreement shall have the
meanings as set forth in Section 13. All other terms contained in this Agreement, unless
otherwise indicated, shall have the meanings provided by the Code, to the extent such terms are
defined therein.

2. LOANS AND TERMS OF PAYMENT 

     2.1 Promise to Pay.

     Borrower hereby unconditionally promises to pay Lenders the unpaid principal amount of all
Credit Extensions hereunder with all interest, fees and finance charges due thereon as and when due
in accordance with this Agreement.

     2.1.1 Equipment Advances.

     (a) Availability. Subject to the terms and conditions of this Agreement, Lenders
agree, severally and not jointly, to lend to Borrower from time to time prior to the Equipment —
Commitment Termination Date, advances (each an “Equipment Advance” and collectively the “Equipment
Advances”) in an aggregate amount not to exceed the Equipment Commitment Amount according to each
Lender’s pro rata share of the Equipment Commitment Amount (based upon the respective Equipment
Commitment Percentage of each Lender). When repaid, the Equipment Advances may not be re-borrowed.
Lenders’ obligation to make Equipment Advances shall terminate on the earlier of (i) the occurrence
and continuance of an Event of Default, or (ii) the Equipment Commitment Termination Date. The
Equipment Advances: (i) may only be used to finance or refinance Eligible Equipment purchased on or
after 90 days before the date of each Equipment Advance (determined based upon the applicable
invoice date of such Eligible Equipment) except for the first Equipment Advance only which may be
used to finance or refinance Eligible Equipment purchased on or after September 30, 2004
(determined based upon the applicable invoice date of such Eligible Equipment), and (ii) may not
exceed one hundred percent (100%) of the Original Stated Cost of the Financed Equipment plus Other
Equipment. Other Equipment may constitute up to 35% of the aggregate Equipment Advances.

1.

 

Each
Equipment Advance must be for a minimum of Two Hundred Thousand Dollars ($200, 000),
however, Borrower may make a single Equipment Advance of less than $200,000 in any given quarter so
long as it is the only Equipment Advance during that quarter.

     (b) Procedure. To obtain an Equipment Advance, Borrower must notify Agent (the notice
is irrevocable) by facsimile no later than 12:00 p.m. Pacific time ten (10) Business Days before
the day on which the Equipment Advance is to be made. Borrower shall deliver to Agent the notice in
the form of Exhibit B (Payment/Advance Form) signed by a Responsible Officer or designee
and include copies of the invoices for the Financed Equipment being financed. On the Equipment
Advance Funding Date, each Lender shall credit or transfer (as applicable) to Borrower’s deposit
account, an amount equal to its Equipment Commitment Percentage multiplied by the amount of the
Equipment Advance. Each Lender may make Equipment Advances under this Agreement based on
instructions from a Responsible Officer or his or her designee or without instructions if the
Equipment Advances are necessary to meet Obligations which have become due. Each Lender may rely on
any telephone notice given by a person — whom such Lender believes is a Responsible Officer or
designee. Borrower shall indemnify each Lender for any loss Lender suffers due to such reliance.

     2.1.2 Growth Capital Loan Facility.

     (a) Availability. Subject to the terms and conditions of this Agreement, Lenders
agree, severally and not jointly, to lend to Borrower from time to time prior to the Growth Capital
Commitment Termination Date, advances (each a “Growth Capital Advance” and collectively the “Growth
Capital Advances”) in an aggregate amount not to exceed the Growth Capital Loan Commitment
according to each Lender’s pro rata share of the Growth Capital Loan Commitment (based upon the
respective Growth Capital Commitment Percentage of each Lender). When repaid, the Growth Capital
Advances may not be re-borrowed. Lenders’ obligation to lend hereunder shall terminate on the
earlier of (i) the occurrence and continuance of an Event of Default, or (ii) the Growth Capital
Commitment Termination Date. For purposes of this Section, the minimum amount of each Growth
Capital Advance is Two Hundred Fifty Thousand Dollars ($250,000).

     (b) Borrowing Procedure. To obtain a Growth Capital Advance, Borrower must notify
Agent by facsimile or telephone by 12:00 p.m. Pacific Time five (5) Business Days prior to the date
the Growth Capital Advance is to be made. If such notification is by telephone, Borrower must
promptly confirm the notification by delivering to Agent a completed Payment/Advance Form in the
form attached as Exhibit B. On the Growth Capital Funding Date, each Lender shall credit or
transfer (as applicable) to Borrower’s deposit account, an amount equal to its Growth Capital
Commitment Percentage multiplied by the amount of the Growth Capital Advance. Each Lender may make
Growth Capital Advances under this Agreement based on instructions from a Responsible Officer or
his or her designee or without instructions if the Growth Capital Advances are necessary to meet
Obligations which have become due. Each Lender may rely on any telephone notice given by a person
whom such Lender believes is a Responsible Officer or designee. Borrower shall indemnify each
Lender for any loss Lender suffers due to such reliance.

2.

 

     2.2 Termination of Commitment to Lend.

     Each Lender’s obligation to lend the undisbursed portion of the Obligations shall terminate
if, in such Lender’s sole discretion made in good faith, there has been a material adverse change
in the general affairs, management, results of operation, condition (financial or otherwise) or the
prospect of repayment of the Obligations, or there has been any material adverse deviation by
Borrower from the most recent business plan of Borrower presented to and accepted by Agent prior to
the execution of this Agreement. Lender shall give Borrower notice promptly of any such Lender’s
decision.

     2.3 Repayment of Credit Extensions on Equipment Advances and Growth Capital Advances.

     (a) Principal and Interest Payments on Payment Dates.

          (i) Equipment Advances. For each Equipment Advance, Borrower shall make monthly
payments of interest only on the then outstanding principal balance commencing on the first
Business Day of the month following the month in which the Equipment Advance Funding Date occurs
(or commencing on the Equipment Advance Funding Date if the Equipment Advance Funding Date is the
first Business Day of the month) with respect to such Equipment Advance and continuing thereafter
on the first Business Day of each successive calendar month (each an “Equipment Interest Only
Payment Date”) during the Equipment Interest Only Period. Commencing on the Equipment Advance
Amortization Date, Borrower shall make forty-two (42) equal monthly payments of principal and
interest which would fully amortize the outstanding Equipment Advances as of the Equipment Advance
Amortization Date over the Equipment Advance Repayment Period (individually, the “Scheduled
Equipment Payment, ” and collectively, “Scheduled Equipment Payments”), on the first Business Day
of each successive month (each a “Scheduled Equipment Payment Date”). All unpaid principal and
accrued interest is due and payable in full on the Equipment Advance Maturity Date. An Equipment
Advance may only be prepaid in accordance with Sections 2.3(e) and 2.3(f). Each Equipment
Interest Only Payment Date and each Scheduled Equipment Payment Date are sometimes referred to as
an “Equipment Payment Date.”

          (ii) Growth Capital Advance. For each Growth Capital Advance, Borrower shall make
monthly payments of interest only on the then outstanding principal balance commencing on the first
Business Day of the month following the month in which the Growth Capital Funding Date occurs (or
commencing on the Growth Capital Funding Date if the Growth Capital Funding Date is the first
Business Day of the month) with respect to such Growth Capital Advance and continuing thereafter on
the first Business Day of each successive calendar month (each a “Growth Capital Interest Only
Payment Date”) during the Growth Capital Interest Only Period. Commencing on the Growth Capital
Amortization Date, Borrower shall make forty-two (42) equal monthly payments of principal and
interest which would fully amortize the outstanding Growth Capital Advances as of the Growth
Capital Amortization Date over the Growth Capital Repayment Period (individually, the “Growth
Capital Scheduled Payment, ” and collectively, “Growth Capital Scheduled Payments”) on the first
Business Day of each successive month and continuing thereafter during the Growth Capital Repayment
Period on the first Business Day of each successive calendar month (each a “Growth Capital
Scheduled

3.

 

Payment Date “). All unpaid principal and accrued interest is due and payable in full on the
Growth Capital Maturity Date. A Growth Capital Advance may only be prepaid in accordance with
Sections 2.3(e) and 2.3(f). Each Growth Capital Interest Only Payment Date and each Growth
Capital Scheduled Payment Date are sometimes referred to as a “Growth Capital Payment Date.”

          (iii) Payments received as to an Equipment Advance or a Growth Capital Advance after 12:00
noon Pacific time are considered received at the opening of business on the next Business Day.

     (b) Interest Rate.

          (i) Equipment Advances. Borrower shall pay interest on each Equipment Payment Date on
the unpaid principal amount of each Equipment Advance until the Equipment Advance has been paid in
full, at the fixed rate equal to two percent (2.0%) per annum in excess of the Prime Rate as of the
date of the Equipment Advance Funding Date, determined by Agent for each Equipment Advance.
Interest is computed on the basis of a 365 day year for the actual number of days elapsed.

          (ii) Growth Capital Loans. Borrower shall pay interest on each Growth Capital Payment
Date on the unpaid principal amount of each Growth Capital Advance until the Growth Capital Advance
has been paid in full, at the fixed rate equal to two percent (2.0%) per annum in excess of the
Prime Rate as of the date of the Growth Capital Funding Date, determined by Agent for each Growth
Capital Advance. Interest is computed on the basis of a 365 day year for the actual number of days
elapsed.

          (iii) Default Rate. Any amounts outstanding under the Equipment Advances or Growth
Capital Loans during the continuance of an Event of Default shall bear interest at a per annum rate
equal to the Default Rate.

     (c) Intentionally Omitted.

     (d) Final Payment.

          (i) Equipment Advances. On the earlier of the occurrence of an Event of Default or the
Equipment Advance Maturity Date with respect to each Equipment Advance, Borrower shall pay, in
addition to the unpaid principal and accrued interest and all other amounts due on such date with
respect to such Equipment Advance, an amount equal to the Equipment Advance Final Payment.

          (ii) Growth Capital Advance. On the Growth Capital Maturity Date with respect to each
Growth Capital Advance, Borrower shall pay, in addition to the unpaid principal and accrued
interest and all other amounts due on such date with respect to such Growth Capital Advance, an
amount equal to the Growth Capital Final Payment.

     (e) Mandatory Payment upon an Acceleration. If the Equipment Advances and the Growth
Capital Advances are accelerated following the occurrence of an Event of Default or otherwise,
Borrower shall immediately pay to Lenders an amount equal to the sum of: (i) all

4.

 

outstanding principal plus accrued interest, (ii) the Final Payment, plus (iii) all other
sums, if any, that shall have become due and payable, including interest at the Default Rate with
respect to any past due amounts.

     (f) Permitted Prepayment of Loans. Borrower shall have the option to prepay all, but
not less than all, of the Equipment Advances or the Growth Capital Advances advanced by Lenders
under this Agreement, provided Borrower (i) provides written notice to Agent of its election to
prepay the Equipment Advances or the Growth Capital Advances at least thirty (30) days prior to
such prepayment, and (ii) pays, on the date of such prepayment (A) all outstanding principal plus
accrued interest, (B) the Final Payment, plus (C) all other sums, if any, that shall have become
due and payable, including interest at the Default Rate with respect to any past due amounts.

     (g) Debit of Accounts. Agent may debit any of Borrower’s deposit accounts including
Account Number 3300465692 for principal and interest payments or any amounts Borrower owes any of
the Lenders. Agent will promptly notify Borrower when it debits Borrower’s accounts. These debits
shall not constitute a set-off.

     2.4 Fees.

     Borrower will pay to Agent all Agent Expenses and Lenders Expenses (including reasonable
attorneys’ fees and reasonable expenses) incurred through and after the Effective Date, when due.

     2.5 Additional Costs. If any new law or regulation increases any Lender’s costs or reduces
its income for any loan, Borrower shall pay the increase in cost or reduction in income or
additional expense; provided, however, that Borrower shall not be liable for any amount
attributable to any period before 180 days prior to the date Agent notifies Borrower of such
increased costs. Agent agrees that it shall allocate any increased costs among its customers
similarly affected in good faith and in a manner consistent with Agent’s customary practice.

3. CONDITIONS OF LOANS 

     3.1 Conditions Precedent to Initial Credit Extension.

     The Lenders’ agreement to make the initial Credit Extension is subject to the condition
precedent that Agent shall have received, in form and substance satisfactory to Agent, such
documents and completion of such other matters, as Agent may reasonably deem necessary or
appropriate, including, without limitation, subject to the condition precedent that Agent shall
have received in form and substance satisfactory to the Agent the following:

     (a) this Agreement;

     (b) a certificate of the Secretary of Borrower with respect to articles, by-laws, incumbency
and resolutions authorizing the execution and delivery of this Agreement;

     (c) Perfection Certificate(s) by Borrower,

5.

 

     (d) Warrants to Purchase Stock;

     (e) financing statements (Forms UCC-I);

     (f) Account Control Agreement/Investment Account Control Agreements (SVB and other financial
institutions);

     (g) VC/OC (Management) Letter Agreement;

     (h) insurance certificate;

     (i) payment of the Agent Expenses and Lenders Expenses then due specified in Section
2.4 hereof;

     (j) Certificate of Foreign Qualification (if applicable);

     (k) Certificate of Good Standing/Legal Existence; and

     (l) such other documents, and completion of such other matters, as Agent may reasonably deem
necessary or appropriate.

     3.2 Conditions Precedent to all Credit Extensions.

     The obligations of Lenders to make each Credit Extension, including the initial Credit
Extension, is subject to the following:

     (a) timely receipt of any Payment/Advance Form;

     (b) For each Growth Capital Advance, a Warrant to Purchase Stock for SVB in the form of
Exhibit C for the number of shares of Series B Preferred Stock equal to 0.333% of such
Growth Capital Advance divided by $1.40 (rounded to the nearest whole number) duly executed and
delivered by Borrower.

     (c) For each Growth Capital Advance, a Warrant to Purchase Stock for Gold Hill in the form of
Exhibit D for the number of shares of Series B Preferred Stock equal to 1.667% of each
Growth Capital Advance divided by $1.40 (rounded to the nearest whole number) duly executed and
delivered by Borrower.

     (d) the representations and warranties in Section 5 shall be materially true on the
date of the Payment/Advance Form and on the effective date of each Credit Extension and no Event of
Default shall have occurred and be continuing, or result from the Credit Extension. Each Credit
Extension is Borrower’s representation and warranty on that date that the representations and
warranties in Section 5 remain true.

6.

 

4. CREATION OF SECURITY INTEREST 

     4.1 Grant of Security Interest. Borrower hereby grants Agent, for the ratable benefit of the
Lenders; and to each Lender, to secure the payment and performance in full of all of the
Obligations and the performance of each of Borrower’s duties under the Loan Documents, a continuing
security interest in, and pledges and assigns to the Agent, for the ratable benefit of the Lenders,
and to each Lender the Collateral, wherever located, whether now owned or hereafter acquired or
arising, and all proceeds and products thereof. Borrower warrants and represents that the security
interest granted herein shall be a first priority security interest in the Collateral. Agent may
place a “hold” on any deposit account pledged as Collateral.

     Borrower agrees that any disposition of the Collateral in violation of this Agreement, by
either the Borrower or any other Person, shall be deemed to violate the rights of the Lenders under
the Code. If the Agreement is terminated, Lenders’ and Agent’s lien and security interest in the
Collateral shall continue until Borrower fully satisfies its Obligations. If Borrower shall at any
time, acquire a commercial tort claim, Borrower shall promptly notify Agent in a writing signed by
Borrower of the brief details thereof and grant to Agent and Lenders in such writing a security
interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such
writing to be in form and substance satisfactory to Agent.

     4.2 Authorization to File Financing Statements.

     Borrower hereby authorizes Agent to file financing statements, without notice to Borrower,
with all appropriate jurisdictions, in order to perfect or protect Agent’s and Lenders’ interest or
rights hereunder.

5. REPRESENTATIONS AND WARRANTIES 

     Borrower represents and warrants to Agent and each Lender as follows:

     5.1 Due Organization and Authorization.

     Borrower and each Subsidiary is duly existing and in good standing in its state of formation
and qualified and licensed to do business in, and in good standing in, any state in which the
conduct of its business or its ownership of property requires that it be qualified, except where
the failure to do so could not reasonably be expected to cause a Material Adverse Change. In
connection with this Agreement, the Borrower delivered to the Agent a certificate signed by the
Borrower and entitled “Perfection Certificate.” The Borrower represents and warrants to the Agent
and each Lender that: (a) the Borrower’s exact legal name is that indicated on the Perfection
Certificate and on the signature page hereof; (b) the Borrower is an organization of the type, and
is organized in the jurisdiction, set forth in the Perfection Certificate; (c) the Perfection
Certificate accurately sets forth the Borrower’s organizational identification number or accurately
states that the Borrower has none; (d) the Perfection Certificate accurately sets forth the
Borrower’s place of business, or, if more than one, its chief executive office as well as the
Borrower’s mailing address if different, and (e) all other information set forth on the Perfection
Certificate pertaining to the Borrower is accurate and complete. If the Borrower does not now have
an organizational identification number, but later obtains one, Borrower shall forthwith notify the
Agent of such organizational identification number.

7.

 

     The execution, delivery and performance of the Loan Documents have been duly authorized, and
do not conflict with Borrower’s organizational documents, nor constitute an event of default under
any material agreement by which Borrower is bound. Borrower is not in default under any agreement
to which or by which it is bound in which the default could reasonably be expected to cause a
Material Adverse Change.

     5.2 Collateral.

     Borrower has good title to the Collateral, free of Liens except Permitted Liens. Borrower has
no deposit account, other than the deposit accounts with Lenders and deposit accounts described in
the Perfection Certificate delivered to Agent in connection herewith. The Accounts are bona fide,
existing obligations, and the service or property has been performed or delivered to the account
debtor or its agent for immediate shipment to and unconditional acceptance by the account debtor.
The Collateral is not in the possession of any third party bailee (such as a warehouse). Except as
hereafter disclosed to the Lenders in writing by Borrower, none of the components of the Collateral
shall be maintained at locations other than as provided in the Perfection Certificate. In the event
that Borrower, after the date hereof, intends to store or otherwise deliver any portion of the
Collateral to a bailee, then Borrower will first receive the written consent of Lenders and such
bailee must acknowledge in writing that the bailee is holding such Collateral for the benefit of
Agent and Lenders. All Inventory is in all material respects of good and marketable quality, free
from material defects.

     5.3 Litigation.

     Except as shown in the Perfection Certificate, there are no actions or proceedings pending or,
to the knowledge of Borrower’s Responsible Officers or legal counsel, threatened by or against
Borrower or any Subsidiary in which an adverse decision could reasonably be expected to cause a
Material Adverse Change.

     5.4 No Material Deterioration in Financial Statements.

     All consolidated financial statements for Borrower, and any Subsidiary, delivered to Agent
fairly present in all material respects Borrower’s consolidated financial condition and Borrower’s
consolidated results of operations. There has not been any material deterioration in Borrower’s
consolidated financial condition since the date of the most recent financial statements a submitted
to Agent.

     5.5 Solvency.

     The fair salable value of Borrower’s assets (including goodwill minus disposition costs)
exceeds the fair value of its liabilities; the Borrower is not left with unreasonably small capital
after the transactions in this Agreement; and Borrower is able to pay its debts (including trade
debts) as they mature.

     5.6 Regulatory Compliance.

     Borrower is not an “investment company” or a company “controlled” by an “investment company”
under the Investment Company Act. Borrower is not engaged as one of its important

8.

 

activities in extending credit for margin stock (under Regulations T and U of the Federal
Reserve Board of Governors). Borrower has complied in all material respects with the Federal Fair
Labor Standards Act. Borrower has not violated any laws, ordinances or rules, the violation of
which could reasonably be expected to cause a Material Adverse Change. None of Borrower’s or any
Subsidiary’s properties or assets has been used by Borrower or any Subsidiary or, to the best of
Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or
transporting any hazardous substance other than legally. Borrower and each Subsidiary has timely
filed all required tax returns and paid, or made adequate provision to pay, all material taxes,
except those being contested in good faith with adequate reserves under GAAP. Borrower and each
Subsidiary has obtained all consents, approvals and authorizations of, made all declarations or
filings with, and given all notices to, all government authorities that are necessary to continue
its business as currently conducted, except where the failure to make such declarations, notices or
filings would not reasonably be expected to cause a Material Adverse Change.

     5.7 Subsidiaries.

     Borrower does not own any stock, partnership interest or other equity securities except for
Permitted Investments.

     5.8 Full Disclosure.

     No written representation, warranty or other statement of Borrower in any certificate or
written statement given to Agent or any Lender (taken together with all such written certificates
and written statements given to Agent or any Lender) contains any untrue statement of a material
fact or omits to state a material fact necessary to make the statements contained in the
certificates or statements not misleading, it being recognized by Agent that the projections and
forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed
as facts and that actual results during the period or periods covered by such projections and
forecasts may differ from the projected or forecasted results.

6. AFFIRMATIVE COVENANTS 

     Borrower shall do all of the following for so long as Agent or any Lender has an obligation to
make any Credit Extension, or there are outstanding Obligations:

     6.1 Government Compliance.

     Borrower shall maintain its and all Subsidiaries’ legal existence and good standing as a
Registered Organization and maintain qualification in each jurisdiction in which the failure to so
qualify would reasonably be expected to have a material adverse effect on Borrower’s business or
operations. Borrower shall comply, and have each Subsidiary comply, with all laws, ordinances and
regulations to which it is subject, noncompliance with which would reasonably be expected to cause
a Material Adverse Change.

9.

 

     6.2 Financial Statements, Reports, Certificates.

     (a) Borrower shall deliver to Agent: (i) as soon as available, but no later than thirty (30)
days after the last day of each month, a company prepared consolidated balance sheet and income
statement covering Borrower’s consolidated operations during the period certified by a Responsible
Officer and in a form acceptable to Agent; (ii) as soon as available, but no later than one hundred
eighty (180) days after the last day of Borrower’s fiscal year, audited consolidated financial
statements prepared under GAAP, consistently applied, together with an unqualified opinion on the
financial statements from an independent certified public accounting firm reasonably acceptable to
Agent; (iii) annual financial projections approved by Borrower’s Board of Directors consistent in
form and detail with those provided to Borrower’s venture capital investors as soon as available,
but no later than thirty (30) days after Board approval; (iv) in the event that the Borrower’s
stock becomes publicly held, upon request by Agent (a) within five (5) days of filing, copies of
all statements, reports and notices made available to Borrower’s security holders or to any holders
of Subordinated Debt and all reports on Form 10-K, 10-Q and 8-K filed with the Securities and
Exchange Commission, and (b) budgets, sales projections, operating plans or other financial
information reasonably requested by Agent; and (v) a prompt report of any legal actions pending or
threatened against Borrower or any Subsidiary that could result in damages or costs to Borrower or
any Subsidiary of One Hundred Thousand Dollars ($100,000.00) or more.

     (b) Upon an Event of Default, allow Agent to audit Borrower’s Collateral at Borrower’s
expense. Such audits shall be conducted no more often than once every twelve (12) months unless an
Event of Default has occurred and is continuing.

     6.3 Inventory; Returns.

     Borrower shall keep all Inventory in good and marketable condition, free from material
defects. Returns and allowances between Borrower and its account debtors shall follow Borrower’s
customary practices as they exist at the Effective Date.

     6.4 Taxes.

     Borrower shall make, and cause each Subsidiary to make, timely payment of all material
federal, state, and local taxes or assessments (other than taxes and assessments which Borrower is
contesting in good faith, with adequate reserves maintained in accordance with GAAP) and will
deliver to Agent, on demand, appropriate certificates attesting to such payments.

     6.5 Insurance.

     Borrower shall keep its business and the Collateral insured for risks and in amounts standard
for companies in Borrower’s industry and location and as Lenders and Agent may reasonably request.
Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to
Lenders and Agent. All property policies shall have a lender’s loss payable endorsement showing
each Lender as an additional loss payee and waive subrogation against Lenders, and all liability
policies shall show, or have endorsements showing, each Lender as an additional insured. All
policies (or the loss payable and additional insured endorsements) shall provide that the insurer
must give Lenders at least twenty (20) days notice before canceling,

10.

 

amending, or declining to renew its policy. At Agent’s request, Borrower shall deliver
certified copies of policies and evidence of all premium payments. Proceeds payable under any
policy shall, at Agent’s option, be payable to Agent on behalf of Lenders on account of the
Obligations. If Borrower fails to obtain insurance as required under this Section 6.5 or to
pay any amount or furnish any required proof of payment to third persons and Agent, Agent may make
all or part of such payment or obtain such insurance policies required in this Section 6.5,
and take any action under the policies Agent deems prudent.

     6.6 Accounts.

     (a) Borrower shall maintain Borrower’s primary operating account with Agent.

     (b) Borrower shall identify to Agent, in writing, any bank or securities account opened by
Borrower with any institution other than Agent. In addition, for each such account that the
Borrower at any time opens or maintains, Borrower shall, at the Agent’s on behalf of Lenders
request and option, pursuant to an agreement in form and substance acceptable to the Lenders and
Agent cause the depository bank or securities intermediary to agree that such account is the
collateral of the Agent, on behalf of Lenders pursuant to the terms hereunder. The provisions of
the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll
taxes and other employee wage and benefit payments to or for the benefit of the Borrower’s
employees.

     6.7 Intellectual Property.

     Borrower shall: (i) protect, defend and maintain the validity and enforceability of the
Intellectual Property; (ii) promptly advise Lenders in writing of material infringements of the
Intellectual Property; and (iii) not allow any Intellectual Property material to the Borrower’s
business to be abandoned, forfeited or dedicated to the public except where Borrower in the
exercise of its business judgment deems it in its best interests.

     6.8 Further Assurances.

     Borrower shall execute any further instruments and take further action as Agent reasonably
requests to perfect or continue Agent’s for the benefit of Lenders security interest in the
Collateral or to effect the purposes of this Agreement.

     6.9 Right to Invest.

     Borrower shall permit Lenders or their respective Affiliates a right (but not an obligation),
in each of Borrower’s subsequent rounds of equity financing, to purchase the securities sold in
each such financing at the same price and on the same terms and conditions as paid and received by
the lead investor of such equity financing in an amount up to one percent (1%) of the securities
sold in each such financing. Borrower shall give Lenders with at least 30 days prior written notice
of each subsequent equity financing containing the terms, conditions and pricing of each such
equity financing. Notwithstanding the foregoing, the Borrower may, at its sole discretion, decline
the Lenders’ offer to participate in Borrower’s subsequent rounds of equity financing.

11.

 

     6.10 Changes in Locations of Collateral.

     Borrower shall provide at least thirty (30) days prior written notice to Agent if Borrower
shall: (i) relocate its chief executive office, or add any new offices or business locations,
including warehouses (unless such new offices or business locations contain less than Five Thousand
Dollars ($5,000) in Borrower’s assets or property), or (ii) change its jurisdiction of
organization, or (iii) change its organizational structure or type, or (iv) change its legal name,
or (v) change any organizational number (if any) assigned by its jurisdiction of organization.

7. NEGATIVE COVENANTS 

     Borrower shall not do any of the following without the Agent’s prior written consent for so
long as Agent or any Lender has an obligation to make Credit Extensions or there are any
outstanding Obligations:

     7.1 Dispositions.

     Convey, sell, lease, transfer or otherwise dispose of (collectively a “Transfer”), or permit
any of its Subsidiaries to Transfer, all or any part of its business or property, except for
Transfers of (i) Inventory in the ordinary course of business; (ii) non-exclusive licenses and
similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary
course of business and other non-perpetual licenses that may be exclusive in some respects, such
as, by way of example, with respect to field of use or geographic territory, but that do not
result, under applicable law, in a sale of all of Borrower’s interest in the property that is the
subject of the license; or (iii) worn-out or obsolete Equipment; (iv) licenses with Intuitive
Surgical, Inc. or NewCo as more specifically described in that certain Term Sheet for Formation of
NewCo and License Agreement dated May 9, 2005 (the “JV Agreement”); and (v) Transfers of direct or
indirect interests in the JV in accordance with the terms of the JV Agreement.

     7.2 Changes in Business, Ownership, or Management.

     Engage in or permit any of its Subsidiaries to engage in any business other than the
businesses currently engaged in by Borrower or reasonably related thereto, or have a change in its
ownership greater than 49% (other than by the sale of Borrower’s equity securities in a public
offering or to venture capital investors so long as Borrower identifies to Agent the venture
capital investors prior to the closing of the investment).

     7.3 Mergers or Acquisitions.

     Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any
other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of
the capital stock or property of another Person without Lenders’ consent which will not be
unreasonably withheld, conditioned or delayed. A Subsidiary may merge or consolidate into another
Subsidiary or into Borrower.

12.

 

     7.4 Indebtedness.

     Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so,
other than Permitted Indebtedness.

     7.5 Encumbrance.

     (a) Except for Permitted Liens: (i) create, incur, or allow any Lien on any of its property,
or assign or convey any right to receive income, including the sale of any Accounts, or permit any
of its Subsidiaries to do so, or (ii) permit any Collateral not to be subject to the first priority
security interest granted herein. The Collateral may be subject to Permitted Liens.

     (b) Except as permitted by Section 7.1, Borrower shall not: (i) sell, transfer,
assign, mortgage, pledge, lease, grant a security interest in, or encumber any of Borrower’s
Intellectual Property, or (ii) enter into any agreement with any Person which prohibits Borrower
from granting a security interest to Agent and Lenders in any of Borrower’s Intellectual Property
or Borrower’s interest in the JV in the event that sometime in the future Borrower elects to grant
such a security interest to Lenders and Agent.

     7.6 Investments; Distributions.

     (a) Investments. Directly or indirectly acquire or own any Person, or make any
Investment in any Person, other than Permitted Investments, or permit any of its Subsidiaries to do
so.

     (b) Distributions. Pay any dividends or make any distribution or payment or redeem,
retire or purchase any capital stock, other than: (i) repurchases of stock from former employees,
consultants or directors of Borrower under the terms of applicable repurchase agreements in an
aggregate amount not to exceed Two Hundred Thousand Dollars ($200,000) in any fiscal year, provided
that no Event of Default has occurred and is continuing or would exist after giving effect to the
repurchases, and (ii) distributions, dividends, payments or redemptions payable solely in capital
stock of Borrower.

     7.7 Transactions with Affiliates.

     Directly or indirectly enter into or permit to exist any material transaction with any
Affiliate of Borrower except for transactions that are in the ordinary course of Borrower’s
business, upon fair and reasonable terms that are no less favorable to Borrower than would be
obtained in an arm’s length transaction with a non-affiliated Person.

     7.8 Subordinated Debt.

     Make or permit any payment on any Subordinated Debt, except under the terms of the
Subordinated Debt, or amend any provision in any document relating to the Subordinated Debt without
Agent’s prior written consent.

13.

 

     7.9 Compliance.

     Become an “investment company” or a company controlled by an “investment company”, under the
Investment Company Act of 1940 or undertake as one of its important activities extending credit to
purchase or carry margin stock, or use the proceeds of any Credit Extension for that purpose; fail
to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited
Transaction, as defined in ERISA, to occur, fail to comply with the Federal Fair Labor Standards
Act or violate any other law or regulation, if the violation could reasonably be expected to have a
material adverse effect on Borrower’s business or operations or would reasonably be expected to
cause a Material Adverse Change, or permit any of its Subsidiaries to do so.

8. EVENTS OF DEFAULT 

     Any one of the following is an Event of Default:

     8.1 Payment Default.

     Borrower fails to pay any of the Obligations within three (3) days after their due date.
During the additional period the failure to cure the default shall not constitute an Event of
Default (but no Credit Extension shall be made during such cure period).

     8.2 Covenant Default.

     (a) If Borrower fails to perform any obligation under Section 6.7 or violates any of
the covenants contained in Section 7 of this Agreement, or

     (b) If Borrower fails or neglects to perform, keep, or observe any other material term,
provision, condition, covenant, or agreement contained in this Agreement, in any of the Loan
Documents, or in any other present or future agreement between Borrower and any Lender and as to
any default under such other term, provision, condition, covenant or agreement that can be cured,
has failed to cure such default within ten (10) days after the occurrence thereof; provided,
however, that if the default cannot by its nature be cured within the ten (10) day period or cannot
after diligent attempts by Borrower be cured within such ten (10) day period, and such default is
likely to be cured within a reasonable time, then Borrower shall have an additional reasonable
period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and
within such reasonable time period the failure to have cured such default shall not be deemed an
Event of Default (provided that no Credit Extensions will be made during such cure period).

     8.3 Intentionally omitted.

     8.4 Attachment.

           (i) Any material portion of Borrower’s assets is attached, seized, levied on, or comes into
possession of a trustee or receiver and the attachment, seizure or levy is not removed in ten (10)
days; (ii) the service of process upon the Borrower seeking to attach, by trustee or similar
process, any funds of the Borrower on deposit with the Lenders or Agent, or any entity under the
control of Lenders or Agent (including a subsidiary); (iii) Borrower is enjoined,

14.

 

restrained, or prevented by court order from conducting a material part of its business; (iv)
a judgment or other claim becomes a Lien on a material portion of Borrower’s assets; or (v) a
notice of lien, levy, or assessment is filed against any of Borrower’s assets by any government
agency and not paid within ten (10) days after Borrower receives notice. These are not Events of
Default if stayed or if a bond is posted pending contest by Borrower (but no Credit Extensions
shall be made during the cure period).

     8.5 Insolvency.

           (i) Borrower is unable to pay its debts (including trade debts) as they mature; (ii) Borrower
begins an Insolvency Proceeding; or (iii) an Insolvency Proceeding is begun against Borrower and
not dismissed or stayed within thirty (30) days (but no Credit Extensions shall be made before any
Insolvency Proceeding is dismissed).

     8.6 Other Agreements.

     If there is a default in any agreement to which Borrower is a party with a third party or
parties resulting in a right by such third party or parties, whether or not exercised, to
accelerate the maturity of any Indebtedness in an amount in excess of Two Hundred Fifty Thousand
Dollars ($250,000) or that could result in a Material Adverse Change.

     8.7 Judgments.

     If a judgment or judgments for the payment of money in an amount, individually or in the
aggregate, of at least Two Hundred Thousand Dollars ($200,000) shall be rendered against Borrower
and shall remain unsatisfied and unstayed for a period of ten (10) days (provided that no Credit
Extensions will be made prior to the satisfaction or stay of such judgment).

     8.8 Misrepresentations.

     If Borrower or any Person acting for Borrower makes any material misrepresentation or material
misstatement now or later in any warranty or representation in this Agreement or in any writing
delivered to Agent or Lenders or to induce Agent or Lenders to enter this Agreement or any Loan
Document.

     8.9 Intentionally Omitted.

     8.10 Lien Priority.

     There is a material impairment in the priority of Agent’s or any Lender’s security interest in
the Collateral.

9. RIGHTS AND REMEDIES 

     9.1 Rights and Remedies.

     When an Event of Default occurs and continues Agent may, without notice or demand, do any or
all of the following:

15.

 

     (a) Declare all Obligations immediately due and payable (but if an Event of Default described
in Section 8.4 occurs all Obligations are immediately due and payable without any action by
Agent or Lenders);

     (b) Stop advancing money or extending credit for Borrower’s benefit under this Agreement or
under any other agreement between Borrower and Agent or Lenders;

     (c) Settle or adjust disputes and claims directly with account debtors for amounts, on terms
and in any order that Agent considers advisable and notify any Person owing Borrower money of
Agent’s for the benefit of Lenders’ security interest in such funds and verify the amount of such
account. Borrower shall collect all payments in trust for Agent for the benefit of Lenders and, if
requested by Agent, immediately deliver the payments to Lenders in the form received from the
account debtor, with proper endorsements for deposit;

     (d) Make any payments and do any acts it considers necessary or reasonable to protect its
security interest in the Collateral. Borrower shall assemble the Collateral if Agent requests and
make it available as Agent designates. Agent may enter premises where the Collateral is located,
take and maintain possession of any part of the Collateral, and pay, purchase, contest, or
compromise any Lien which appears to be prior or superior to its security interest and pay all
expenses incurred. Borrower grants Agent for the benefit of Lenders a license to enter and occupy
any of its premises, without charge, to exercise any of Agent’s rights or remedies;

     (e) Apply to the Obligations any (i) balances and deposits of Borrower it holds, or (ii) any
amount held by Agent or Lenders owing to or for the credit or the account of Borrower;

     (f) Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for
sale, and sell the Collateral. Agent is hereby granted a non-exclusive, royalty-free license or
other right to use, without charge, Borrower’s labels, patents, copyrights, mask works, rights of
use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or
any similar property as it pertains to the Collateral, in completing production of, advertising for
sale, and selling any Collateral and, in connection with Agent’s exercise of its rights under this
Section, Borrower’s rights under all licenses and all franchise agreements inure to Agent’s for
benefit of Lenders; and

     (g) Place a “hold” on any account maintained with Agent or deliver a notice of exclusive
control, any entitlement order, or other directions or instructions pursuant to any control
agreement or similar agreements providing control of any Collateral; and

     (h) Dispose of the Collateral according to the Code.

     9.2 Power of Attorney.

     Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact, to be effective
upon the occurrence and during the continuance of an Event of Default, to: (i) endorse Borrower’s
name on any checks or other forms of payment or security; (ii) sign Borrower’s name on any invoice
or bill of lading for any Account or drafts against account debtors, (iii) settle and adjust
disputes and claims about the Accounts directly with account debtors, for

16.

 

amounts and on terms Agent determines reasonable; (iv) make, settle, and adjust all claims
under Borrower’s insurance policies; and (v) transfer the Collateral into the name of Agent for the
benefit of Lenders or a third party as the Code permits. Borrower hereby appoints Agent as its
lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue
the perfection of any security interest regardless of whether an Event of Default has occurred
until all Obligations have been satisfied in full and Agent and Lenders are under no further
obligation to make Credit Extensions hereunder. Agent’s foregoing appointment as Borrower’s
attorney in fact, and all of Agent’s rights and powers, coupled with an interest, are irrevocable
until all Obligations have been fully repaid and performed and Lenders’ and Agent’s obligation to
provide Credit Extensions terminates.

     9.3 Accounts, Notification and Collection.

     In the event that an Event of Default occurs and is continuing, Agent may notify any Person
owing Borrower money of Agent’s, and Lenders’ security interest in the funds and verify and collect
the amount of the Account. After the occurrence of an Event of Default, any amounts received by
Borrower shall be held in trust by Borrower for Agent, and, if requested by Agent, Borrower shall
immediately deliver such receipts to Agent in the from received from the account debtor, with
proper endorsements for deposit.

     9.4 Agent Expenses.

     Any amounts paid by Agent as provided herein are Agent Expenses and are immediately due and
payable and shall bear interest at the then applicable rate and be secured by the Collateral. No
payments by Agent shall be deemed an agreement to make similar payments in the future or Agent’s
and Lenders’ waiver of any Event of Default.

     9.5 Agent’s and Lenders’ Liability for Collateral.

     So long as the Agent and Lenders comply with reasonable banking practices regarding the
safekeeping of Collateral, the Agent and Lenders shall not be liable or responsible for: (a) the
safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the
value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other
Person. Borrower bears all risk of loss, damage or destruction of the Collateral.

     9.6 Remedies Cumulative.

     Agent’s rights and remedies under this Agreement, the Loan Documents, and all other agreements
are cumulative. Agent has all rights and remedies provided under the Code, by law, or in equity.
Agent’s exercise of one right or remedy is not an election, and Agent’s waiver of any Event of
Default is not a continuing waiver. Agent’s delay is not a waiver, election, or acquiescence. No
waiver hereunder shall be effective unless signed by Agent and each Lender and then is only
effective for the specific instance and purpose for which it was given.

     9.7 Demand Waiver.

     Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment,
notice of any default, nonpayment at maturity, release, compromise, settlement,

17.

 

extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held
by Agent on which Borrower is liable.

10. NOTICES 

     Notices or demands by either party about this Agreement must be in writing and personally
delivered or sent by an overnight delivery service, or by certified mail, postage prepaid, return
receipt requested, or by telefacsimile at the addresses listed below. A party may change its notice
address by written notice to the other party.

	 	 	 	 	 
	 

	 	If to Borrower:
	 	Hansen Medical, Inc.
	 

	 	 	 	380 North Bernardo Avenue
	 

	 	 	 	Mountain View, California 94043
	 

	 	 	 	Attn: Larry J. Strauss
	 

	 	 	 	Fax: (650) 404-5900
	 
	 	 	 	 
	 

	 	If to Agent:
	 	Silicon Valley Bank
	 

	 	or SVB:
	 	2400 Geng Road, Suite 200
	 

	 	 	 	Palo Alto, California 94303
	 

	 	 	 	Attn: Chris Wagner
	 

	 	 	 	Fax: (650) 320-0016
	 
	 	 	 	 
	 

	 	If to Gold Hill:
	 	Gold Hill Venture Lending Partners
	 

	 	 	 	3003 Tasman Drive
	 

	 	 	 	Santa Clara, California 95054
	 

	 	 	 	Attn: Tim McDonough
	 

	 	 	 	Fax: (408) 654-6256

11. CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

     California law governs the Loan Documents without regard to principles of conflicts of law.
Borrower and Lenders, and Agent each submit to the exclusive jurisdiction of the State and Federal
courts in California and Borrower accepts jurisdiction of the courts and venue in Santa Clara
County, California. NOTWITHSTANDING THE FOREGOING, THE LENDERS OR AGENT SHALL HAVE THE RIGHT TO
BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER
JURISDICTION WHICH THE AGENT DEEMS NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL
OR TO OTHERWISE ENFORCE THE LENDERS’ OR AGENT’S RIGHTS AGAINST THE BORROWER OR ITS PROPERTY.

     BORROWER, AGENT, AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF
ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED
TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A
MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS
WAIVER WITH ITS COUNSEL.

18.

 

12. GENERAL PROVISIONS 

     12.1 Successors and Assigns.

     This Agreement binds and is for the benefit of the successors and permitted assigns of each
party. Borrower may not assign this Agreement or any rights or Obligations under it without Agent’s
prior written consent which may be granted or withheld in Agent’s discretion. Lenders and Agent
have the right, without the consent of or notice to Borrower, to sell, transfer, assign, negotiate,
or grant participation in all or any part of, or any interest in, Lenders’ obligations, rights and
benefits under this Agreement, the Loan Documents or any related agreement, including, without
limitation, an assignment to any Affiliate or related party.

     12.2 Indemnification.

     Borrower hereby indemnifies, defends and holds Agent and the Lenders and their respective
officers, employees, and agents harmless against: (a) all obligations, demands, claims, and
liabilities asserted by any other party in connection with the transactions contemplated by the
Loan Documents; and (b) all losses, Agent Expenses, or Lenders Expenses incurred, or paid by
Lenders or Agent from, following, or consequential to transactions between Lenders and Borrower
(including reasonable attorneys’ fees and expenses), except for losses caused by Lender’s or
Agent’s gross negligence or willful misconduct.

     12.3 Attorneys’ Fees, Costs and Expenses.

     In any action or proceeding between Borrower and Agent arising out of the Loan Documents the
prevailing party will be entitled to recover its reasonable attorneys’ fees and other reasonable
costs and expenses incurred, in addition to any other relief to which it may be entitled.

     12.4 Right of Set-Off.

     Borrower and any guarantor hereby grant to Agent for the ratable benefit of Lenders, a lien,
security interest and right of set-off as security for all Obligations to Agent and each Lender,
hereunder, whether now existing or hereafter arising upon and against all deposits, credits,
collateral and property, now or hereafter in the possession, custody, safekeeping or control of
Agent or any entity under the control of the Agent (including an Agent subsidiary) or in transit to
any of them. At any time after the occurrence and during the continuance of an Event of Default,
without demand or notice, Agent may set-off the same or any part thereof and apply the same to any
liability or obligation of Borrower and any guarantor even though unmatured and regardless of the
adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE AGENT TO
EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS,
PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF
THE BORROWER OR ANY GUARANTOR, ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.

19.

 

     12.5 Time of Essence.

     Time is of the essence for the performance of all Obligations in this Agreement.

     12.6 Severability of Provision.

     Each provision of this Agreement is severable from every other provision in determining the
enforceability of any provision.

     12.7 Amendments in Writing, Integration.

     All amendments to this Agreement must be in writing signed by both Agent and Borrower. This
Agreement and the Loan Documents represent the entire agreement about this subject matter, and
supersede prior negotiations or agreements. All prior agreements, understandings, representations,
warranties, and negotiations between the parties about the subject matter of this Agreement and the
Loan Documents merge into this Agreement and the Loan Documents.

     12.8 Counterparts.

     This Agreement may be executed in any number of counterparts and by different parties on
separate counterparts, each of which, when executed and delivered, are an original, and all taken
together, constitute one Agreement.

     12.9 Survival.

     All covenants, representations and warranties made in this Agreement continue in full force
while any Obligations remain outstanding. The obligations of Borrower to indemnify any Lender and
Agent, including without limitation Section 12.2, shall survive until the statute of
limitations with respect to such claim or cause of action shall have run. The obligations of
Borrower under Section 6.9, shall survive until they are, by their terms, no longer
operative.

     12.10 Confidentiality.

     In handling any confidential information, Lenders and Agent shall exercise the same degree of
care that it exercises for its own proprietary information, but disclosure of information may be
made: (i) to Lenders’ and Agent’s subsidiaries or affiliates in connection with their business with
Borrower; (ii) to prospective transferees or purchasers of any interest in the Credit Extensions
(provided, however, Lenders and Agent shall use commercially reasonable efforts in obtaining such
prospective transferee’s or purchaser’s agreement to the terms of this provision); (iii) as
required by law, regulation, subpoena, or other order, (iv) as required in connection with Lenders’
and Agent’s examination or audit; and (v) as Agent considers appropriate in exercising remedies
under this Agreement. Confidential information does not include information that either: (a) is in
the public domain or in Lenders’ or Agent’s possession when disclosed to Lenders or Agent, or
becomes part of the public domain after disclosure to Lenders or Agent through no fault of Agent or
such Lender, or (b) is disclosed to Lenders or Agent by a third party, if Lenders or Agent does not
know that the third party is prohibited from disclosing the information.

20.

 

     12.11 Effective Date.

     Notwithstanding anything set forth in this Agreement or any Loan Document to the contrary,
this Agreement and all of the Loan Documents shall not be effective until the date on which the
Agent and each Lender executes this Agreement as indicated on the signature page to this Agreement.

13. DEFINITIONS 

     13.1 Definitions.

     In this Agreement:

     “Accounts” are all existing and later arising accounts, contract rights, and other obligations
owed Borrower in connection with its sale or lease of goods (including licensing software and other
technology) or provision of services, all credit insurance, guaranties, other security and all
merchandise returned or reclaimed by Borrower and Borrower’s Books relating to any of the
foregoing, as such definition may be amended from time to time according to the Code.

     “Affiliate” is a Person that owns or controls directly or indirectly the Person, any Person
that controls or is controlled by or is under common control with the Person, and each of that
Person’s senior executive officers, directors, partners and, for any Person that is a limited
liability company, that Person’s managers and members.

     “Agent” means, SVB, not in its individual capacity, but solely in its capacity as agent on
behalf of and for the benefit of the Lenders.

     “Agent Expenses” are all audit fees and expenses and reasonable costs or expenses (including
reasonable attorneys’ fees and expenses) for preparing, negotiating, administering, defending and
enforcing the Loan Documents (including appeals or Insolvency Proceedings).

     “Borrower’s Books” are all Borrower’s books and records including ledgers, records regarding
Borrower’s assets or liabilities, the Collateral, business operations or financial condition and
all computer programs or discs or any equipment containing the information.

     “Business Day” is any day that is not a Saturday, Sunday or a day on which the Agent is
closed.

     “Code” is the Uniform Commercial Code as adopted in California as amended and in effect from
time to time.

     “Collateral” is any and all properties, rights and assets of the Borrower granted by the
Borrower to Lenders or arising under the Code, now, or in the future, described on Exhibit
A.

     “Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or
not, of that Person for (i) any indebtedness, lease, dividend, letter of credit or other obligation
of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted
or

21.

 

sold with recourse by that Person, or for which that Person is directly or indirectly liable;
(ii) any obligations for undrawn letters of credit for the account of that Person; and (iii) all
obligations from any interest rate, currency or commodity swap agreement, interest rate cap or
collar agreement, or other agreement or arrangement designated to protect a Person against
fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent
Obligation” does not include endorsements in the ordinary course of business. The amount of a
Contingent Obligation is the stated or determined amount of the primary obligation for which the
Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability
for it determined by the Person in good faith; but the amount may not exceed the maximum of the
obligations under the guarantee or other support arrangement.

     “Copyrights” are all copyright rights, applications or registrations and like protections in
each work or authorship or derivative work, whether published or not (whether or not it is a trade
secret) now or later existing created, acquired or held.

     “Credit Extension” is each Equipment Advance, Growth Capital Advance or any other extension of
credit by any Lender for Borrower’s benefit.

     “Default Rate” means for each Equipment Advance and Growth Capital Advance, five percent (5%)
above the highest rate otherwise applicable thereto.

     “Dollars” and “$” each means the lawful currency of the Untied States

     “Effective Date” is the date SVB executes this Agreement and as indicated on the signature
page hereof.

     “Eligible Equipment” is (a) new and used general purpose computer equipment, office equipment,
manufacturing equipment, test and laboratory equipment, furnishings, subject to the limitations set
forth herein, and (b) Other Equipment that complies with all of Borrower’s representations and
warranties to Agent and which is reasonably acceptable to Agent in all respects.

     “Equipment” is all present and future machinery, equipment, tenant improvements, furniture,
fixtures, vehicles, tools, parts and attachments in which Borrower has any interest.

     “Equipment Advance” is defined in Section 2.1.1 (a).

     “Equipment Advance Amortization Date” means April 1, 2006.

     “Equipment Advance Final Payment” is a payment (in addition to and not a substitution for the
regular monthly payments of principal plus accrued interest) due on the Equipment Advance Maturity
Date for such Equipment Advance equal to the Equipment Advance Loan Amount for such Equipment
Advance multiplied by the Equipment Advance Final Payment Percentage.

     “Equipment Advance Final Payment Percentage” is, for each Equipment Advance, one and one-half
percent (1.5%).

22.

 

     “Equipment Advance Funding Date” is any date on which an Equipment Advance is made to or on
account of Borrower.

     “Equipment Advance Loan Amount” in respect to each Equipment Advance is the original principal
amount of such Equipment Advance.

     “Equipment Advance Maturity Date” is, for each Equipment Advance, the earliest of (a)
September 1, 2009, or (b) the occurrence of an Event of Default.

     “Equipment Advance Repayment Period” is a period of time equal to forty-two (42) consecutive
months commencing on April 1, 2006.

     “Equipment Commitment Amount” is One Million Dollars ($1,000,000).

     “Equipment Commitment Percentage” means: (i) 25% with respect to SVB, and (ii) 75% with
respect to the Gold Hill.

     “Equipment Commitment Termination Date” is March 31, 2006.

     “Equipment Interest Only Period” means, for each Equipment Advance, the period of time
commencing on its Equipment Advance Funding Date through the day before the Equipment Advance
Amortization Date.

     “Equipment Payment Date” is defined in Section 2.3(a).

     “Final Payment” means the Equipment Advance Final Payment and the Growth Capital Advance Final
Payment.

     “Financed Equipment” is all present and future Eligible Equipment in which Borrower has any
interest, the purchase of which is financed by an Equipment Advance.

     “GAAP” is generally accepted accounting principles.

     “Growth Capital Advance” or “Growth Capital Advances” is defined in Section 2.1.2(a).

     “Growth Capital Amortization Date” means January 1, 2006.

     “Growth Capital Commitment Percentage” means: (i) 16.67% with respect to SVB, and (ii) 83.33%
with respect to the Gold Hill.

     “Growth Capital Commitment Termination Date” is December 31, 2005.

     “Growth Capital Final Payment” is a payment (in addition to and not a substitution for the
regular monthly payments of principal plus accrued interest) due on the Growth Capital Maturity
Date for such Growth Capital Advance equal to the Growth Capital Loan Amount for such Growth
Capital Advance multiplied by the Growth Capital Advance Final Payment Percentage.

23.

 

     “Growth Capital Final Payment Percentage” is, for each Growth Capital Advance, two and
one-half percent (2.5%).

     “Growth Capital Funding Date” is any date on which a Growth Capital Advance is made to or on
account of Borrower.

     “Growth Capital Interest Only Period” means, for each Growth Capital Advance, the period of
time commencing on its Growth Capital Funding Date through the day before the Growth Capital
Amortization Date.

     “Growth Capital Loan Amount” in respect to each Growth Capital Advance is the original
principal amount of such Growth Capital Advance.

     “Growth Capital Loan Commitment” is Six Million Dollars ($6,000,000).

     “Growth Capital Maturity Date” is, for each Growth Capital Advance, the earliest of (a) June
1, 2009, or (b) the occurrence of an Event of Default.

     “Growth Capital Payment Date” is defined in Section 2.3(a)(ii).

     “Growth Capital Repayment Period” is a period of time equal to forty-two (42) consecutive
months commencing on January 1, 2006.

     “Guarantor” is any present or future guarantor of the Obligations.

     “Indebtedness” is (a) indebtedness for borrowed money or the deferred price of property or
services, such as reimbursement and other obligations for surety bonds and letters of credit, (b)
obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease
obligations and (d) Contingent Obligations.

     “Insolvency Proceeding” is any proceeding by or against any Person under the United States
Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit
of creditors, compositions, extensions generally with its creditors, or proceedings seeking
reorganization, arrangement, or other relief.

     “Intellectual Property” is:

     (a) Copyrights, Trademarks and Patents, and Mask Works including amendments, renewals,
extensions, and all licenses or other rights to use and all license fees and royalties from the
use;

     (b) Any trade secrets and any intellectual property rights in computer software and computer
software products now or later existing, created, acquired or held;

     (c) All design rights which may be available to Borrower now or later created, acquired or
held;

24.

 

     (d) Any claims for damages (past, present or future) for infringement of any of the rights
above, with the right, but not the obligation, to sue and collect damages for use or infringement
of the intellectual property rights above;

     (e) (e) All Proceeds and products of the foregoing, including all insurance, indemnity or
warranty payments.

     “Inventory” is present and future inventory in which Borrower has any interest, including
merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and
finished products intended for sale or lease or to be furnished under a contract of service, of
every kind and description now or later owned by or in the custody or possession, actual or
constructive, of Borrower, including inventory temporarily out of its custody or possession or in
transit and including returns on any accounts or other proceeds (including insurance proceeds) from
the sale or disposition of any of the foregoing and any documents of title.

     “Investment” is any beneficial ownership of (including stock, partnership interest or other
securities) any Person, or any loan, advance or capital contribution to any Person.

     “JV” means Borrower’s joint venture with Intuitive Surgical, Inc. as more specifically
described in that certain Term Sheet for Formation of NewCo and License Agreement dated May 9,
2005.

     “Lenders Expenses” are all audit fees and expenses and reasonable costs or expenses (including
reasonable attorneys’ fees and expenses) for preparing, negotiating, administering, defending and
enforcing the Loan Documents (including appeals or Insolvency Proceedings).

     “Letter-of-Credit Right” means a right to payment or performance under a letter of credit,
whether or not the beneficiary has demanded or is at the time entitled to demand payment or
performance.

     “Lien” is a mortgage, lien, deed of trust, charge, pledge, security interest or other
encumbrance.

     “Loan Documents” are, collectively, this Agreement, any note, or notes or guaranties executed
by Borrower or Guarantor, and any other present or future agreement between Borrower or Guarantor
for the benefit of Lenders and Agent in connection with this Agreement, all as amended, extended or
restated.

     “Mask Works” are all mask works or similar rights available for the protection of
semiconductor chips, now owned or later acquired.

     “Material Adverse Change” is: (i) a material impairment in the perfection or priority of
Lenders’ security interest in the Collateral or in the value of such Collateral; (ii) a material
adverse change in the business, operations, or condition (financial or otherwise) of the Borrower,
or (iii) a material impairment of the prospect of repayment of any portion of the Obligations.

25.

 

     “Obligations” are debts, principal, interest, the Final Payments, Agent Expenses, Lenders
Expenses, and other amounts Borrower owes either of the Lenders or Agent now or later, including
cash management services, letters of credit and foreign exchange contracts, if any and including
interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of
Borrower assigned to Lenders or Agent.

     “Original Stated Cost” is (a) with respect to each item of Eligible Equipment, the original
cost to Borrower of the item of new Eligible Equipment net of any and all freight, installation,
tax, or the fair market value assigned to such item of used Eligible Equipment by mutual agreement
of Borrower and Agent at the time of making of the Equipment Advance, and (b) with respect to each
item of Other Equipment, the original cost to Borrower of the item of Other Equipment.

     “Other Equipment” is leasehold improvements, intangible property such as computer software and
software licenses, equipment specifically designed or manufactured for Borrower, other intangible
property, limited use property and other similar and soft costs approved by Agent, including sales
tax, freight and installation expenses.

     “Patents” are patents, patent applications and like protections, including improvements,
divisions, continuations, renewals, reissues, extensions and continuations in part of the same.

     “Permitted Indebtedness” is:

     (a) Borrower’s indebtedness to Lenders and Agent under this Agreement or the Loan Documents;

     (b) Indebtedness existing on the Effective Date and shown on the Perfection Certificate;

     (c) Indebtedness incurred by Borrower owed to a third party subordinated to Borrower’s
Indebtedness owed to Agent or any Lender which subordination is reflected in a written agreement as
accepted and approved by Agent prior to the incurrence of such third party Indebtedness, which
acceptance and approval shall not be unreasonably withheld, conditioned or delayed;

     (d) Indebtedness to trade creditors incurred in the ordinary course of business; and

     (e) Indebtedness secured by Permitted Liens;

     (f) Indebtedness arising from the endorsement of negotiable instruments for deposit or
collection or similar transactions in the ordinary course of business;

     (g) Extensions, refinancings, modifications, amendments and restatements of any items of
Permitted Indebtedness (a) through (f) above, provided that the then outstanding principal amount
thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon
Borrower or its Subsidiary, as the case may be.

26.

 

     “Permitted Investments” are:

     (a) Investments shown on the Perfection Certificate and existing on the Effective Date; and

     (b) (i) marketable direct obligations issued or unconditionally guaranteed by the United
States or its agency or any state maturing within 1 year from its acquisition, (ii) commercial
paper maturing no more than 1 year after its creation and having the highest rating from either
Standard & Poor’s Corporation or Moody’s Investors Service, Inc., (iii) Agent’s certificates of
deposit issued maturing no more than 1 year after issue, (iv) any other investments administered
through the Lenders, and (v) Investments permitted by Borrower’s investment policy, as amended from
time to time provided that such investment policy (and such amendment thereto) has been approved by
Agent in writing (which approval shall not be unreasonably withheld, conditioned or delayed);

     (c) Investments consisting of the endorsement of negotiable instruments for deposit or
collection or similar transactions in the ordinary course of Borrower,

     (d) Investments consisting of (i) travel advances and employee relocation loans and other
employee loans and advances in the ordinary course of business which shall not exceed $250,000 in
the aggregate in any fiscal year, and (ii) non-cash loans to employees, officers or directors
relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee
stock purchase plans or agreements approved by Borrower’s Board of Directors;

     (e) Investments consisting of deposit accounts and investment accounts of Borrower in which
Agent has a Lien perfected through an account control agreement, which Lien is prior to any other
Liens (other than Liens securing the customary fees and expenses of the depository or investment
intermediary);

     (f) (i) Investments of Subsidiaries in or to other Subsidiaries or Borrower and (ii)
Investments by Borrower in Subsidiaries in an amount not to exceed Five Hundred Thousand Dollars
($500,000) in any fiscal year;

     (g) Other Investments not otherwise permitted by Section 7.6 not exceeding $25,000 in
the aggregate outstanding at any time; and

     (h) Investments which shall not in the aggregate exceed $3,500,000 in the JV and, to the
extent they may be considered Investments, Transfers permitted by Section 7.1 (iv).

     “Permitted Liens” are:

     (a) Liens existing on the Effective Date and shown on the Perfection Certificate or arising
under this Agreement or other Loan Documents;

     (b) Liens for taxes, fees, assessments or other government charges or levies, either not
delinquent or being contested in good faith and for which Borrower maintains adequate reserves on
its Books, if they have no priority over any of Agent’s security interests;

27.

 

     (c) Purchase money Liens (i) on Equipment other than Financed Equipment acquired or held
by Borrower incurred for financing the acquisition of such Equipment, or (ii) existing on equipment
when acquired, if the Lien is confined to the property and improvements and the proceeds of such
Equipment.

     (d) Liens in favor of other financial institutions arising in connection with Borrower’s
deposit accounts or investment accounts held at such institutions to secure customary fees and
charges (but not credit/debt relationships or margin accounts), provided that Agent has a perfected
security interest via an account control agreement in the amounts held in such accounts;

     (e) Statutory Liens securing claims or demands of materialmen, mechanics, carriers,
warehousemen, landlords and other Person imposed without action of such parties, provided they have
no priority over any of Agent’s and Lender’s security interests and the aggregate amount of such
Lien does not at any time exceed $25,000;

     (f) Liens arising from the filing of any financing statement on operating leases, to the
extent such operating leases are permitted under this Agreement;

     (g) Liens on cash collateral securing reimbursement obligations to Agent under letters of
credit;

     (h) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in
title and similar charges or encumbrances affecting real property not likely to result in a
Material Adverse Change; and

     (i) Licenses and sub-licenses granted by Borrower in the ordinary course of business and not
otherwise prohibited by this Agreement.

     “Person” is any individual, sole proprietorship, partnership, limited liability company, joint
venture, company association, trust, unincorporated organization, association, corporation,
institution, public benefit corporation, firm, joint stock company, estate, entity or government
agency.

     “Prime Rate” is SVB’s most recently announced “prime rate, ” even if it is not SVB’s lowest
rate.

     “Proceeds” has the meaning described in the Code as in effect from time to time.

     “Registered Organization” means an organization organized solely under the law of a single
state or the United States and as to which the state or the United States must maintain a public
record showing the organization to have been organized.

     “Responsible Officer” is each of the Chief Executive Officer, President, Chief Financial
Officer and the Controller of Borrower.

     “Subordinated Debt” is debt incurred by Borrower subordinated to Borrower’s debt to Lenders
(pursuant to a subordination agreement entered into between the Agent, the Borrower

28.

 

and the subordinated creditor), on terms acceptable to Agent which acceptance shall not be
unreasonably withheld, conditioned or delayed.

     “Subsidiary” is any Person, corporation, partnership, limited liability company, joint
venture, or any other business entity of which more than 50% of the voting stock or other equity
interests is owned or controlled, directly or indirectly, by the Person or one or more Affiliates
of the Person.

     “Supporting Obligation” means a Letter-of-Credit Right, secondary obligation or obligation of
a secondary obligor or that supports the payment or performance of an account, chattel paper, a
document, a general intangible, an instrument or investment property.

     “Trademarks” are trademark and service mark rights, registered or not, applications to
register and registrations and like protections, and the entire goodwill of the business of
Assignor connected with the trademarks.

(Signatures are on the following page)

29.

 

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the
date first above written.

	 	 	 	 	 	 	 
	 	 	BORROWER:	 	 
	 
	 	 	 	 	 	 
	 	 	HANSEN MEDICAL, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Larry J. Strauss	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Larry J. Strauss	 	 
	 

	 	 	 	Title: Chief Financial Officer	 	 
	 
	 	 	 	 	 	 
	 	 	AGENT:	 	 
	 	 	SILICON VALLEY BANK	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Christopher Wagner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Christopher Wagner	 	 
	 

	 	 	 	Title:	 	 
	 
	 	 	 	 	 	 
	 	 	LENDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	GOLD HILL VENTURE LENDING 03, LP	 	 
	 	 	By: Gold Hill Venture Lending Partners 03,
 LLC
General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Sean Lynden	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Sean Lynden	 	 
	 

	 	 	 	Manager	 	 
	 
	 	 	 	 	 	 
	 	 	SILICON VALLEY BANK	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Christopher Wagner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Christopher Wagner	 	 
	 

	 	 	 	Title:	 	 

Effective as of August 5, 2005

30.

 

EXHIBIT A

     The Collateral consists of all right, title and interest of Borrower in and to the following:

     All goods, equipment, inventory, contract rights or rights to payment of money, license
agreements, franchise agreements, general intangibles (including payment intangibles), accounts
(including health-care receivables), documents, instruments (including any promissory notes),
chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures, letters of credit
rights (whether or not the letter of credit is evidenced by a writing), commercial tort claims,
securities, and all other investment property, financial assets, whether now owned or hereafter
acquired, wherever located; all Supporting Obligations and all of the Borrower’s Books relating to
the foregoing and any and all claims, rights and interests in any of the above and all
substitutions for, additions and accessions to and Proceeds thereof.

     All Letter-Of-Credit Rights (whether or not the letter of credit is evidenced by a writing);
and

Notwithstanding the foregoing, the Collateral does not include:

(1) any of Borrower’s direct or indirect interest in the joint venture with Intuitive
Surgical, Inc. as more specifically described in that certain Term Sheet for Formation of
NewCo and License Agreement dated May 9, 2005 (the “JV”), including any direct or indirect
interest of Borrower in any shareholder or joint venture agreements and matters incidental
thereto; provided, however, the Collateral shall include all proceeds arising out of the
sale of Borrower’s direct or indirect interest in the JV, and

(2) any direct or indirect interest in Intellectual Property, provided, however, the
Collateral shall include all accounts, license and royalty fees and other revenues,
proceeds, or income arising out of or relating to any of the foregoing Intellectual
Property.

 

EXHIBIT B

Loan Payment/Advance Request Form

	 	 	 
	Fax To:                                         

	 	Date:

	 	 	 	 	 	 	 	 	 	 	 
	 	LOAN PAYMENT:
	 	 	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	 

	 	 	 	 	 	(Borrower)	 	 	 
	 	 

	 	 	 
	 	From Account #	 	 	 	 	 	To Account #
	 
	 	(Deposit Account #)	 	 	 	 	 	(Loan Account #)
	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Principal $

	 	and Interest $	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	     All Borrower’s representation and warranties in the Loan and Security Agreement are true, correct
and complete in all material respects on the date of the telephone transfer request for an advance,
but those representations and warranties expressly referring to another date shall be true, correct
and complete in all material respects as of such date:	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Authorized Signature:

	 	 	 	Phone Number:	 	 	 	 	 
	 
	 
	 	 	 	 	 	 	 	 	 
	 	Loan Advance: 
	 	 	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an
outgoing wire.	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	From Account #	 	 	 	 	 	To Account #
	 
	 	(Loan Account #)	 	 	 	 	 	(Deposit Account #)
	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Amount of Advance $
	 	 	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	All Borrower’s representation and warranties in the Loan and Security Agreement are true correct and complete
in all material respects on the date of the telephone transfer request for an advance, but those
representations and warranties expressly referring to another date shall be true, correct and complete in all
material respects as of such date:	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Authorized Signature:

	 	 	 	Phone Number:	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Outgoing Wire Request
	 	 	 	 	 	 	 	 	 
	 	Complete only if all or a portion of funds from the loan advance above are to be wired.	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Deadline for same day processing is 12:00 pm, P.S.T.	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Beneficiary Name:	 	Amount of Wire: $	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Beneficiary Bank:	 	Account Number:	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	City and State:
	 	 	 	 	 	 	 	 	 
	 	 
	 	 	 	 	 	 	 	 	 
	 	Beneficiary Bank Transit (ABA) #: __ __ __ __ __ __ __ __. Beneficiary Bank Code (Swift, Sort, Chip, etc.):	 
	 	 
	 	 	 	 	 	 	 	 	 

 

	 	 	 	 	 	 	 
	Intermediary Bank:

	 	 	 	(For International Wire Only)
Transit (ABA) #:	 	 
	 
	 	 	 	 	 	 
	For Further Credit to:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Special Instruction:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance
with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which
agreement(s) were previously received and executed by me (us).
	 
	 	 	 	 	 	 
	Authorized Signature:	 	2nd Signature (If Required):	 	 
	 

	 	 	 	 
	 	 
	 
	 	 	 	 	 	 
	Print Name/Title:

	 	Print Name/Title:	 	 	 	 
	 
	 	 	 	 	 	 
	Telephone #

	 	Telephone #	 	 	 	 
	 

	 	 
	 	 

 

EXHIBIT C

FORM OF SVB’S GROWTH CAPITAL ADVANCE WARRANT

 

EXHIBIT D

FORM OF GOLD HILL’S GROWTH CAPITAL ADVANCE WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]